RNA 療法的全球市場:增長機會
市場調查報告書
商品編碼
1090214

RNA 療法的全球市場:增長機會

Global RNA Therapeutics Growth Opportunities

出版日期: | 出版商: Frost & Sullivan | 英文 51 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

核酸療法的科學進步正在對全球生物製藥行業產生重大影響。 RNA(核糖核酸)治療市場有望取得重大臨床進展,因為它針對“無法治愈”的途徑。對技術優勢的日益增長的需求以及建立臨床上優越的 RNA 療法組合以提高競爭力的需求預計將促進 RNA 療法行業利益相關者之間的戰略夥伴關係。

本報告研究和分析全球 RNA 治療市場,並提供有關戰略必要因素、驅動因素、限制因素、主要趨勢、盈利預測、競爭環境、增長機會等方面的信息。

目錄

戰略要素

  • 為什麼增長變得越來越困難?
  • 戰略要素 8 (TM)
  • 三大戰略要素對 RNA 治療行業的影響
  • 增長機會推動增長管道引擎 (TM)

增長機會分析

  • 分析範圍
  • 細分
  • 調查方法
  • 重點
  • 成長指標
  • 增長動力
  • 增長限制
  • 主要趨勢
  • 主要疾病的適應症
  • 2021 年管道快照
  • 價值鏈關鍵利益相關者
  • 主要利益相關者造成混亂
  • 製造商的區域快照
  • 滿足 SM 製造和供應需求的策略
  • 利益相關者在供應鏈中不斷演變的角色
  • RNA 療法生物製造的總體變化
  • 分銷和供應框架
  • 主要合作主題
  • 著名的合作夥伴關係
  • 著名的 mRNA 製造合作夥伴:按地區-歐洲
  • 著名的 mRNA 製造合作夥伴:按地區-美國
  • 預測的先決條件
  • 收入預測
  • 收入預測分析
  • 收入預測:按產品類型
  • 正在開發的主要模式
  • 競爭環境
  • 市場份額分析

增長機會宇宙

  • 增長機會1-增加對免疫腫瘤學的關注以滿足對腫瘤特異性治療的需求
  • 增長機會 2-優化 LNP 遞送以解決 RNA 治療穩定性問題
  • 增長機會 3-擴大 CDMO 能力以支持生物製藥公司
  • 圖表列表
  • 免責聲明
簡介目錄
Product Code: PD2B-52

Future Growth Potential Driven by Co-Development Programs and Robust Clinical Trials for Diverse Disease Areas

Scientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target "undruggable" pathways. Technologically advanced platforms are integrated into RNA therapeutics bioprocessing to overcome stability issues. Technological advantages, coupled with the growing need to build clinically superior portfolios in RNA therapeutics for a competitive edge, are anticipated to drive strategic partnerships among stakeholders in the RNA therapeutics industry.

Spurred by the COVID-19 pandemic, biopharmaceutical companies are likely to prioritize microRNA, small interfering RNA, and antisense oligonucleotides as promising therapeutic modalities during the forecast period. Midsize and large companies have ramped up the production of starting materials and the final formulation of RNA therapeutics, which is likely to propel stakeholders to seek synergistic partnerships. In the industry's transition to personalized therapeutics, RNA developers are capitalizing on the high precision of RNA to treat untapped chronic disease areas such as cystic fibrosis, solid tumors, and spinal muscular atrophy. They engage in co-development programs to improve the stability profile of RNA therapeutics by optimizing drug delivery carriers, such as lipid nanoparticles.

Scaling up the production of starting materials, including plasmid DNA, oligonucleotides, and delivery materials, to ensure continuous manufacturing is anticipated to reduce the operational timeframe of RNA therapeutics production. Technology transfer and the outsourcing of crucial operations to contract development and manufacturing organizations (CDMO) catalyze the development of cost-effective and efficient models for RNA therapeutics.

This Frost & Sullivan research service provides an overview of the global RNA therapeutics industry from 2021 to 2027, including emerging trends, growth drivers, and growth opportunities.

The research service highlights the following:

  • RNA therapeutics market size, including key segments from 2022 to 2027
  • Advancements in bioprocessing, modalities, and technologies that are shaping the market
  • Current and future R&D, investment outlook, and trends

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the RNA Therapeutics Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

  • Scope of Analysis
  • Segmentation
  • Research Methodology
  • Key Takeaways
  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Key Trends
  • Key Disease Indications
  • Pipeline Snapshot for 2021
  • Value Chain-Key Stakeholders
  • Value Chain-Key Stakeholders (continued)
  • Notable Stakeholders Driving Disruption
  • Regional Snapshot of Manufacturers
  • Strategies to Meet SM Manufacturing and Supply Needs
  • Evolving Role of Stakeholders in the Supply Chain
  • Evolving Role of Stakeholders in the Supply Chain (continued)
  • Holistic Changes in RNA Therapeutics Biomanufacturing
  • Distribution and Supply Framework
  • Key Partnership Themes
  • Notable Partnerships
  • Notable Partnerships (continued)
  • Notable mRNA Manufacturing Partnerships by Region-Europe
  • Notable mRNA Manufacturing Partnerships by Region-US
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast Analysis
  • Percent Revenue Forecast by Product Type
  • Key Modalities Under Development
  • Competitive Environment
  • Market Share Analysis

Growth Opportunity Universe

  • Growth Opportunity 1-Increase Focus on Immuno-oncology to Meet the Demand for Tumor-specific Targeted Therapeutics
  • Growth Opportunity 1-Increase Focus on Immuno-oncology to Meet the Demand for Tumor-specific Targeted Therapeutics (continued)
  • Growth Opportunity 2-Optimize LNP Delivery to Address the Stability Issues of RNA Therapeutics
  • Growth Opportunity 2-Optimize LNP Delivery to Address the Stability Issues of RNA Therapeutics (continued)
  • Growth Opportunity 3-Expand CDMO Capabilities to Support Biopharmaceutical Companies
  • Growth Opportunity 3-Expand CDMO Capabilities to Support Biopharmaceutical Companies (continued)
  • Growth Opportunity 3-Expand CDMO Capabilities to Support Biopharmaceutical Companies (continued)
  • List of Exhibits
  • Legal Disclaimer